Plasma 25-hydroxyvitamin D and risk of pancreatic cancer
- PMID: 22086883
- PMCID: PMC3253914
- DOI: 10.1158/1055-9965.EPI-11-0836
Plasma 25-hydroxyvitamin D and risk of pancreatic cancer
Abstract
Background: Laboratory studies suggest that vitamin D may inhibit pancreatic cancer cell growth. However, epidemiologic studies of vitamin D and pancreatic cancer risk have been conflicting.
Methods: To determine whether prediagnostic levels of plasma 25-hydroxyvitamin D (25[OH]D; IDS Inc.; enzyme immunoassay) were associated with risk of pancreatic cancer, we conducted a pooled analysis of nested case-control studies with 451 cases and 1,167 controls from five cohorts through 2008. Median follow-up among controls was 14.1 years in Health Professionals Follow-Up Study (HPFS), 18.3 years in Nurses' Health Study (NHS), 25.3 years in Physicians' Health Study (PHS), 12.2 years in Women's Health Initiative-Observational Study (WHI), and 14.4 years in Women's Health Study (WHS). Logistic regression was used to compare the odds of pancreatic cancer by plasma level of 25(OH)D.
Results: Mean plasma 25(OH)D was lower in cases versus controls (61.3 vs. 64.5 nmol/L, P = 0.005). In logistic regression models, plasma 25(OH)D was inversely associated with odds of pancreatic cancer. Participants in quintiles two through five had multivariable-adjusted ORs (95% confidence intervals) of 0.79 (0.56-1.10), 0.75 (0.53-1.06), 0.68 (0.48-0.97), and 0.67 (0.46-0.97; P(trend) = 0.03), respectively, compared with the bottom quintile. Compared with those with insufficient levels [25[OH]D, <50 nmol/L], ORs were 0.75 (0.58-0.98) for subjects with relative insufficiency [25[OH]D, 50 to <75 nmol/L] and 0.71 (0.52-0.97) for those with sufficient levels [25[OH]D, ≥ 75 nmol/L]. No increased risk was noted in subjects with 25(OH)D ≥100 nmol/L, as suggested in a prior study. In subgroup analyses, ORs for the top versus bottom quartile of 25(OH)D were 0.72 (0.48-1.08) for women, 0.73 (0.40-1.31) for men, and 0.73 (0.51-1.03) for Whites.
Conclusions: Among participants in five large prospective cohorts, higher plasma levels of 25(OH)D were associated with a lower risk for pancreatic cancer.
Impact: Low circulating 25(OH)D may predispose individuals to the development of pancreatic cancer.
Conflict of interest statement
Conflicts of Interest: None
Similar articles
-
Vitamin D-binding protein and pancreatic cancer: a nested case-control study.Am J Clin Nutr. 2015 Jun;101(6):1206-15. doi: 10.3945/ajcn.114.096016. Epub 2015 Apr 22. Am J Clin Nutr. 2015. PMID: 25904602 Free PMC article.
-
Impact of circulating vitamin D binding protein levels on the association between 25-hydroxyvitamin D and pancreatic cancer risk: a nested case-control study.Cancer Res. 2012 Mar 1;72(5):1190-8. doi: 10.1158/0008-5472.CAN-11-2950. Epub 2012 Jan 9. Cancer Res. 2012. PMID: 22232734 Free PMC article.
-
A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts.J Natl Cancer Inst. 2013 Jan 16;105(2):95-103. doi: 10.1093/jnci/djs474. Epub 2012 Dec 14. J Natl Cancer Inst. 2013. PMID: 23243202 Free PMC article.
-
Vitamin D and cancer incidence in the Harvard cohorts.Ann Epidemiol. 2009 Feb;19(2):84-8. doi: 10.1016/j.annepidem.2007.12.002. Epub 2008 Mar 4. Ann Epidemiol. 2009. PMID: 18291673 Review.
-
Vitamin D and pancreatic cancer.Ann Epidemiol. 2009 Feb;19(2):89-95. doi: 10.1016/j.annepidem.2008.03.010. Epub 2008 May 27. Ann Epidemiol. 2009. PMID: 18504144 Free PMC article. Review.
Cited by
-
Sulforaphane and related mustard oils in focus of cancer prevention and therapy.Wien Med Wochenschr. 2013 Feb;163(3-4):80-8. doi: 10.1007/s10354-012-0163-3. Epub 2012 Dec 7. Wien Med Wochenschr. 2013. PMID: 23224634
-
Calcipotriol Targets LRP6 to Inhibit Wnt Signaling in Pancreatic Cancer.Mol Cancer Res. 2015 Nov;13(11):1509-19. doi: 10.1158/1541-7786.MCR-15-0204. Epub 2015 Jul 29. Mol Cancer Res. 2015. PMID: 26224368 Free PMC article.
-
Vitamin D Prevents Pancreatic Cancer-Induced Apoptosis Signaling of Inflammatory Cells.Biomolecules. 2020 Jul 15;10(7):1055. doi: 10.3390/biom10071055. Biomolecules. 2020. PMID: 32679840 Free PMC article.
-
Vitamin D-binding protein and pancreatic cancer: a nested case-control study.Am J Clin Nutr. 2015 Jun;101(6):1206-15. doi: 10.3945/ajcn.114.096016. Epub 2015 Apr 22. Am J Clin Nutr. 2015. PMID: 25904602 Free PMC article.
-
Molecular link between vitamin D and cancer prevention.Nutrients. 2013 Sep 30;5(10):3993-4021. doi: 10.3390/nu5103993. Nutrients. 2013. PMID: 24084056 Free PMC article. Review.
References
-
- Garland CF, Gorham ED, Mohr SB, Garland FC. Vitamin D for cancer prevention: global perspective. Ann Epidemiol. 2009;19(7):468–83. - PubMed
-
- Guallar E, Miller ER, 3rd, Ordovas JM, Stranges S. Vitamin D supplementation in the age of lost innocence. Ann Intern Med. 2010;152(5):327–9. - PubMed
-
- Vieth R, Bischoff-Ferrari H, Boucher BJ, Dawson-Hughes B, Garland CF, Heaney RP, et al. The urgent need to recommend an intake of vitamin D that is effective. Am J Clin Nutr. 2007;85(3):649–50. - PubMed
-
- Schwartz GG, Eads D, Rao A, Cramer SD, Willingham MC, Chen TC, et al. Pancreatic cancer cells express 25-hydroxyvitamin D-1 alpha-hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3. Carcinogenesis. 2004;25(6):1015–26. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- K07 CA148894/CA/NCI NIH HHS/United States
- P01 CA087969/CA/NCI NIH HHS/United States
- N01WH242129-32/WH/WHI NIH HHS/United States
- R01 CA124908/CA/NCI NIH HHS/United States
- CA047988/CA/NCI NIH HHS/United States
- HL080467/HL/NHLBI NIH HHS/United States
- R01 CA040360/CA/NCI NIH HHS/United States
- P50 CA127003/CA/NCI NIH HHS/United States
- R01 CA034944/CA/NCI NIH HHS/United States
- N01WH24152/WH/WHI NIH HHS/United States
- N01WH232105-6/WH/WHI NIH HHS/United States
- R01 HL043851/HL/NHLBI NIH HHS/United States
- N01WH232118-32119/WH/WHI NIH HHS/United States
- P01 CA055075/CA/NCI NIH HHS/United States
- R01 HL034595/HL/NHLBI NIH HHS/United States
- N01 WH022110/WH/WHI NIH HHS/United States
- N01WH42107-26/WH/WHI NIH HHS/United States
- CA97193/CA/NCI NIH HHS/United States
- N01WH232100-2/WH/WHI NIH HHS/United States
- N01WH232122/WH/WHI NIH HHS/United States
- P01 CA87969/CA/NCI NIH HHS/United States
- N01WH232111-13/WH/WHI NIH HHS/United States
- P01 CA55075/CA/NCI NIH HHS/United States
- R01 HL026490/HL/NHLBI NIH HHS/United States
- N01WH232108-9/WH/WHI NIH HHS/United States
- R01 CA047988/CA/NCI NIH HHS/United States
- R01 HL080467/HL/NHLBI NIH HHS/United States
- K07 CA140790/CA/NCI NIH HHS/United States
- R01 CA097193/CA/NCI NIH HHS/United States
- CA40360/CA/NCI NIH HHS/United States
- N01WH232115/WH/WHI NIH HHS/United States
- N01WH44221/WH/WHI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical